Real-World Use of Albutrepenonacog Alfa, A Recombinant Coagulation Factor IX Albumin Fusion Protein, for Personalized Prophylaxis in Japanese Individuals With Hemophilia B: A Case Series

Currently, the mainstay of disease management for hemophilia B, a hemorrhagic disease caused by a congenital deficiency or molecular abnormalities of blood coagulation factor IX (FIX), is prophylaxis using FIX concentrate. On-demand injections of FIX concentrate may also be required, even during pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagao, Azusa, Bingo, Masato, Yamaguchi, Tomoko, Fukutake, Katsuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909124/
https://www.ncbi.nlm.nih.gov/pubmed/36779089
http://dx.doi.org/10.7759/cureus.33573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909124/
https://www.ncbi.nlm.nih.gov/pubmed/36779089
http://dx.doi.org/10.7759/cureus.33573

Ejemplares similares